OncoMatch/Clinical Trials/NCT02535221
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
Is NCT02535221 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Goserelin+TAM+AI and Epirubicin+CTX+5-Fu for breast cancer.
Treatment: Goserelin+TAM+AI · Epirubicin+CTX+5-Fu — This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 ER positive (>50% cell in IHC) (>50% cell in IHC)
Histologically confirmed HR+ (ER or PR positive, and >50% cell in IHC)
Required: PR (PGR) PR positive (>50% cell in IHC) (>50% cell in IHC)
Histologically confirmed HR+ (ER or PR positive, and >50% cell in IHC)
Required: HER2 (ERBB2) negative
HER2 negative breast cancer by pathological evaluation
Disease stage
Required: Stage T2N0M0 (TNM)
Excluded: Stage LYMPH NODE POSITIVE
Stage: T2N0M0(cT>2cm, SLNB negative), hard to proceed the breast conserving surgery(not feasible or may affect the appearance of breast)
Prior therapy
Cannot have received: anti-tumor treatment
No other previous treatment for primary breast cancer; have been attendance in other anti-tumor treatment or other clinical trials
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify